External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy

Autor:	F. Donskov, Wanling Xie, Christian K. Kollmannsberger, Min-Han Tan, Connor Wells, Lauren C. Harshman, D. Y. Heng, Yulei Wang, G. A. Bjarnason, Toni K. Choueiri, Sun Young Rha, Lori Wood, J. Lebert, U. N. Vaishampayan, Brian I. Rini
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Thrombocytosis business.industry Anemia medicine.medical_treatment External validation medicine.disease Surgery Targeted therapy Risk groups Renal cell carcinoma Internal medicine Prognostic model Medicine business Prognostic models
Zdroj:	Journal of Clinical Oncology. 29:4560-4560
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.4560
Popis:	4560 Background: The Heng et al JCO 2009 prognostic model was developed in the age of VEGF-targeted therapy and this study serves as an external validation while comparing its performance to other models. Methods: 1,028 previously unanalyzed patients were used to externally validate the prognostic criteria for overall survival (OS). The model’s discriminatory value was compared to four other prognostic models using C-indices and Net Reclassification Improvement (NRI) (Pencina et al 2008). NRI indicates how the Heng et al model improves upon other models by reclassifying a percentage of patients (pts) into the more correct risk group based on the observed OS at 2 years. Results: The median OS of all pts was 18.8 mons. On multivariable analysis, the pre-identified Heng’s risk factors (anemia, thrombocytosis, neutrophilia, hypercalcemia, Karnofsky performance status
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ea933351fae13ed7ab927658afa4728c https://doi.org/10.1200/jco.2011.29.15_suppl.4560 Zobrazit plný text záznamu